{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:09Z","timestamp":1793397909189,"version":"4.5.0"},"reference-count":115,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,7,5]]},"DOI":"10.1001\/jama.2022.10233","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T11:05:16Z","timestamp":1657019116000},"page":"57","source":"Crossref","is-referenced-by-count":481,"title":["Sickle Cell Disease"],"prefix":"10.1001","volume":"328","author":[{"given":"Patricia L.","family":"Kavanagh","sequence":"first","affiliation":[{"name":"Division of General Pediatrics, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titilope A.","family":"Fasipe","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children\u2019s Hospital, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Wun","sequence":"additional","affiliation":[{"name":"School of Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"16","key":"jrv220010r1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease.","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv220010r2","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease.","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"jrv220010r3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"key":"jrv220010r5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/pathmechdis.2019.14.issue-1","article-title":"Pathophysiology of sickle cell disease.","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"jrv220010r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100637","article-title":"Not all red cells sickle the same: contributions of the reticulocyte to disease pathology in sickle cell anemia.","volume":"40","author":"Carden","year":"2020","journal-title":"Blood Rev"},{"issue":"21","key":"jrv220010r7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMra0804411","article-title":"Pulmonary complications of sickle cell disease.","volume":"359","author":"Gladwin","year":"2008","journal-title":"N Engl J Med"},{"key":"jrv220010r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.05.004","article-title":"Sickle cell disease: clinical presentation and management of a global health challenge.","volume":"37","author":"Houwing","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"jrv220010r9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/ijns4040039","article-title":"Newborn screening for sickle cell disease and other hemoglobinopathies: a short review on classical laboratory methods-isoelectric focusing, HPLC, and capillary electrophoresis.","volume":"4","author":"Fr\u00f6mmel","year":"2018","journal-title":"Int J Neonatal Screen"},{"issue":"6","key":"jrv220010r10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0904","article-title":"Ensuring the life-span benefits of newborn screening.","volume":"144","author":"Kemper","year":"2019","journal-title":"Pediatrics"},{"issue":"5","key":"jrv220010r12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/mi12050519","article-title":"Techniques for the detection of sickle cell disease: a review.","volume":"12","author":"Arishi","year":"2021","journal-title":"Micromachines (Basel)"},{"issue":"25","key":"jrv220010r13","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia. a randomized trial.","volume":"314","author":"Gaston","year":"1986","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv220010r14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.","volume":"339","author":"Adams","year":"1998","journal-title":"N Engl J Med"},{"issue":"9870","key":"jrv220010r15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(12)61726-7","article-title":"The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.","volume":"381","author":"Howard","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"jrv220010r16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202.pub2","article-title":"Hydroxyurea (hydroxycarbamide) for sickle cell disease.","volume":"4","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Sysemat Rev"},{"issue":"18","key":"jrv220010r17","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"jrv220010r18","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"jrv220010r19","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"jrv220010r20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"jrv220010r22","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"jrv220010r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1737","article-title":"Comparison of US federal and foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity.","volume":"3","author":"Farooq","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"jrv220010r24","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1542\/peds.2005-1611","article-title":"Sickle cell disease: a question of equity and quality.","volume":"117","author":"Smith","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"jrv220010r25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease.","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv220010r26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis.","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"jrv220010r27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of L-glutamine in sickle cell disease.","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv220010r28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease.","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv220010r29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia.","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"9778","key":"jrv220010r30","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"jrv220010r31","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial.","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"key":"jrv220010r32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2326-5-4","article-title":"L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells.","volume":"5","author":"Niihara","year":"2005","journal-title":"BMC Blood Disord"},{"issue":"7","key":"jrv220010r33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease.","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv220010r34","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1182\/blood.2019003776","article-title":"Gene therapy for sickle cell disease: moving from the bench to the bedside.","volume":"138","author":"Abraham","year":"2021","journal-title":"Blood"},{"issue":"3","key":"jrv220010r35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease.","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv220010r36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bjh.2018.181.issue-4","article-title":"Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: a British Society for Haematology guideline.","volume":"181","author":"Qureshi","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"jrv220010r37","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3285","article-title":"Hydroxyurea use for sickle cell isease among Medicaid-enrolled children.","volume":"144","author":"Brousseau","year":"2019","journal-title":"Pediatrics"},{"issue":"16","key":"jrv220010r38","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1001\/jama.2015.3075","article-title":"Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.","volume":"313","author":"Stettler","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"jrv220010r39","first-page":"968","article-title":"Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.","volume":"100","author":"Lanzkron","year":"2008","journal-title":"J Natl Med Assoc"},{"issue":"6","key":"jrv220010r40","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v66.6","article-title":"Hydroxyurea use among children with sickle cell anemia.","volume":"66","author":"Reeves","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"jrv220010r41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u00df-thalassemia.","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"jrv220010r42","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v97.7","article-title":"Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study.","author":"van Dijk","year":"2022","journal-title":"Am J Hematol"},{"issue":"17","key":"jrv220010r43","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/blood.2021013674","article-title":"A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.","volume":"139","author":"Rees","year":"2022","journal-title":"Blood"},{"issue":"17","key":"jrv220010r44","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"issue":"22","key":"jrv220010r45","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2017-05-782003","article-title":"Targeting novel mechanisms of pain in sickle cell disease.","volume":"130","author":"Tran","year":"2017","journal-title":"Blood"},{"issue":"18","key":"jrv220010r46","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","article-title":"Sickle cell pain: a critical reappraisal.","volume":"120","author":"Ballas","year":"2012","journal-title":"Blood"},{"issue":"2","key":"jrv220010r47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ajh.24948","article-title":"A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD).","volume":"93","author":"Tanabe","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"jrv220010r48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.7326\/M20-7171","article-title":"Treatment of acute pain in adults with sickle cell disease in an infusion center versus the emergency department: a multicenter prospective cohort study.","volume":"174","author":"Lanzkron","year":"2021","journal-title":"Ann Intern Med"},{"key":"jrv220010r49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/asheducation-2013.1.9","article-title":"The ASH Choosing Wisely\u00aecampaign: five hematologic tests and treatments to question.","volume":"2013","author":"Hicks","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"jrv220010r50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.21550","article-title":"Definitions of the phenotypic manifestations of sickle cell disease.","volume":"85","author":"Ballas","year":"2010","journal-title":"Am J Hematol"},{"issue":"25","key":"jrv220010r51","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease.","volume":"342","author":"Vichinsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv220010r52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0002-9343(94)90136-8","article-title":"Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes.","volume":"96","author":"Hassell","year":"1994","journal-title":"Am J Med"},{"issue":"10019","key":"jrv220010r53","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"jrv220010r54","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776","article-title":"Clinical events in the first decade in a cohort of infants with sickle cell disease.","volume":"86","author":"Gill","year":"1995","journal-title":"Blood"},{"issue":"3","key":"jrv220010r55","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-2182","article-title":"Antibiotic prophylaxis for children with sickle cell anemia.","volume":"141","author":"Reeves","year":"2018","journal-title":"Pediatrics"},{"issue":"4","key":"jrv220010r56","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/bjh.2019.185.issue-4","article-title":"Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature.","volume":"185","author":"Oligbu","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"jrv220010r57","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/pbc.25655","article-title":"Contribution of sickle cell disease to the pediatric stroke burden among hospital discharges of African-Americans-United States, 1997-2012.","volume":"62","author":"Baker","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"jrv220010r58","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors.","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"issue":"5","key":"jrv220010r59","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/pbc.24392","article-title":"National trends in incidence rates of hospitalization for stroke in children with sickle cell disease.","volume":"60","author":"McCavit","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"jrv220010r60","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/archneur.58.4.565","article-title":"Stroke prevention and treatment in sickle cell disease.","volume":"58","author":"Adams","year":"2001","journal-title":"Arch Neurol"},{"issue":"5","key":"jrv220010r61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/bjh.2012.156.issue-5","article-title":"Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients.","volume":"156","author":"Brousse","year":"2012","journal-title":"Br J Haematol"},{"key":"jrv220010r62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2019.102374","article-title":"Prevalence and predictive factors of splenic sequestration crisis among 423 pediatric patients with sickle cell disease in Tunisia.","volume":"80","author":"Ben Khaled","year":"2020","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"jrv220010r63","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/adc.62.6.585","article-title":"Parvovirus associated aplastic crisis in homozygous sickle cell disease.","volume":"62","author":"Goldstein","year":"1987","journal-title":"Arch Dis Child"},{"issue":"1","key":"jrv220010r64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0022-3476(00)90054-4","article-title":"Gallstones in sickle cell disease: observations from the Jamaican Cohort study.","volume":"136","author":"Walker","year":"2000","journal-title":"J Pediatr"},{"issue":"5","key":"jrv220010r65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.hoc.2005.08.003","article-title":"Priapism in sickle cell disease.","volume":"19","author":"Rogers","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"jrv220010r66","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1046\/j.1464-410X.2002.03022.x","article-title":"Priapism in sickle-cell disease; incidence, risk factors and complications\u2014an international multicentre study.","volume":"90","author":"Adeyoju","year":"2002","journal-title":"BJU Int"},{"key":"jrv220010r67","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/j.urology.2021.06.010","article-title":"Priapism and sickle cell disease: special considerations in etiology, management, and prevention.","volume":"156","author":"Ahuja","year":"2021","journal-title":"Urology"},{"issue":"6","key":"jrv220010r68","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bjh.12199","article-title":"How I manage priapism due to sickle cell disease.","volume":"160","author":"Olujohungbe","year":"2013","journal-title":"Br J Haematol"},{"issue":"4 pt 1","key":"jrv220010r69","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/01.ju.0000087608.07371.ca","article-title":"American Urological Association guideline on the management of priapism.","volume":"170","author":"Montague","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"jrv220010r70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004198.pub4","article-title":"Treatments for priapism in boys and men with sickle cell disease.","volume":"4","author":"Chinegwundoh","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"jrv220010r71","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjh.2017.178.issue-2","article-title":"Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.","volume":"178","author":"Brunson","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"jrv220010r72","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ajh.v94.8","article-title":"High incidence of venous thromboembolism recurrence in patients with sickle cell disease.","volume":"94","author":"Brunson","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"jrv220010r73","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/bloodadvances.2017012336","article-title":"Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"issue":"17","key":"jrv220010r74","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2018-03-822593","article-title":"How I diagnose and treat venous thromboembolism in sickle cell disease.","volume":"132","author":"Shet","year":"2018","journal-title":"Blood"},{"issue":"1","key":"jrv220010r75","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/asheducation-2017.1.546","article-title":"Targeting novel mechanisms of pain in sickle cell disease.","volume":"2017","author":"Tran","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"jrv220010r76","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9191","article-title":"Association of opioid dose reduction with opioid overdose and opioid use disorder among patients receiving high-dose, long-term opioid therapy in North Carolina.","volume":"5","author":"Diprete","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"jrv220010r77","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.1002\/ajh.v93.10","article-title":"Opioid utilization patterns in United States individuals with sickle cell disease.","volume":"93","author":"Ballas","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"jrv220010r78","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/can.2018.0001","article-title":"Marijuana use in adults living with sickle cell disease.","volume":"3","author":"Roberts","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"issue":"7","key":"jrv220010r79","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.10874","article-title":"Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial.","volume":"3","author":"Abrams","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"jrv220010r80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/can.2019.0036","article-title":"Daily cannabis users with sickle cell disease show fewer admissions than others with similar pain complaints.","volume":"5","author":"Curtis","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"jrv220010r81","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/can.2017.0011","article-title":"The use of cannabis by patients with sickle cell disease increased the frequency of hospitalization due to vaso-occlusive crises.","volume":"2","author":"Ballas","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"jrv220010r82","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5604\/15093492.992286","article-title":"Avascular necrosis of the femoral head in sickle cell disease patients.","volume":"14","author":"Matos","year":"2012","journal-title":"Ortop Traumatol Rehabil"},{"issue":"16","key":"jrv220010r83","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1182\/bloodadvances.2017005256","article-title":"Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California.","volume":"1","author":"Adesina","year":"2017","journal-title":"Blood Adv"},{"key":"jrv220010r84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004344.pub7","article-title":"Treatment for avascular necrosis of bone in people with sickle cell disease.","volume":"12","author":"Mart\u00ed-Carvajal","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"jrv220010r85","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/BPO.0000000000001953","article-title":"Core decompression and bone marrow aspirate concentrate in the treatment of femoral head avascular necrosis in pediatric sickle cell disease: can we improve natural history?","volume":"41","author":"Griffith","year":"2021","journal-title":"J Pediatr Orthop"},{"key":"jrv220010r86","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jcot.2021.02.010","article-title":"Core decompression with bone marrow aspirate concentrate in post collapse avascular necrosis of hip: a systematic review and meta-analysis.","volume":"17","author":"Jindal","year":"2021","journal-title":"J Clin Orthop Trauma"},{"key":"jrv220010r87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcot.2021.101691","article-title":"Core decompression and bone marrow aspirate concentrate injection for Avascular Necrosis (AVN) of the femoral head: a scoping review.","volume":"24","author":"Pawar","year":"2021","journal-title":"J Clin Orthop Trauma"},{"issue":"6","key":"jrv220010r88","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/ICU.0000000000000423","article-title":"Sickle cell disease and the eye.","volume":"28","author":"Do","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"jrv220010r89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010790.pub2","article-title":"Laser therapy for retinopathy in sickle cell disease.","author":"Myint","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"jrv220010r90","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/ICB.0b013e3182845d31","article-title":"Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment.","volume":"7","author":"Moshiri","year":"2013","journal-title":"Retin Cases Brief Rep"},{"issue":"23","key":"jrv220010r91","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1182\/bloodadvances.2019000883","article-title":"End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv"},{"key":"jrv220010r92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009191.pub4","article-title":"Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.","volume":"12","author":"Sasongko","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv220010r93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ajh.24134","article-title":"Critical reviews: how we treat sickle cell patients with leg ulcers.","volume":"91","author":"Minniti","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"jrv220010r94","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","article-title":"Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.","volume":"127","author":"Gordeuk","year":"2016","journal-title":"Blood"},{"issue":"12","key":"jrv220010r95","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jama.2012.358","article-title":"Mortality in adults with sickle cell disease and pulmonary hypertension.","volume":"307","author":"Mehari","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"jrv220010r96","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1164\/rccm.201207-1222OC","article-title":"Hemodynamic predictors of mortality in adults with sickle cell disease.","volume":"187","author":"Mehari","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"jrv220010r97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.critrevonc.2015.11.018","article-title":"Pregnancy and sickle cell disease: a review of the current literature.","volume":"98","author":"Boga","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"jrv220010r98","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/bjo.v128.10","article-title":"Pregnancy outcome in homozygous sickle cell disease: observations from the Jamaican Birth Cohort.","volume":"128","author":"Lewis","year":"2021","journal-title":"BJOG"},{"issue":"21","key":"jrv220010r99","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1182\/blood-2015-06-649319","article-title":"Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis.","volume":"126","author":"Malinowski","year":"2015","journal-title":"Blood"},{"issue":"2","key":"jrv220010r100","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s10995-012-1216-3","article-title":"Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population.","volume":"17","author":"Boulet","year":"2013","journal-title":"Matern Child Health J"},{"issue":"2","key":"jrv220010r101","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.contraception.2005.08.010","article-title":"Progestogen-only contraceptive use among women with sickle cell anemia: a systematic review.","volume":"73","author":"Legardy","year":"2006","journal-title":"Contraception"},{"issue":"6","key":"jrv220010r102","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/cen.v94.6","article-title":"Compensated hypogonadism in men with sickle cell disease.","volume":"94","author":"Ribeiro","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"jrv220010r103","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000337344","article-title":"Hypogonadism in patients with sickle cell disease: central or peripheral?","volume":"128","author":"Taddesse","year":"2012","journal-title":"Acta Haematol"},{"issue":"24","key":"jrv220010r104","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1182\/blood-2014-07-577619","article-title":"Reproductive issues in sickle cell disease.","volume":"124","author":"Smith-Whitley","year":"2014","journal-title":"Blood"},{"issue":"11","key":"jrv220010r105","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease.","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"jrv220010r106","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/pbc.24557","article-title":"Sickle cell disease related mortality in the United States (1999-2009).","volume":"60","author":"Hamideh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"jrv220010r107","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting.","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"6","key":"jrv220010r109","doi-asserted-by":"publisher","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality.","volume":"41","author":"Grosse","year":"2011","journal-title":"Am J Prev Med"},{"issue":"13","key":"jrv220010r110","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jama.2010.378","article-title":"Acute care utilization and rehospitalizations for sickle cell disease.","volume":"303","author":"Brousseau","year":"2010","journal-title":"JAMA"},{"issue":"8","key":"jrv220010r111","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081154","article-title":"Shared care for adults with sickle cell disease: an analysis of care from eight health systems.","volume":"8","author":"Mainous","year":"2019","journal-title":"J Clin Med"},{"key":"jrv220010r112","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103498","article-title":"Biopsychosocial factors related to transition among adolescents and young adults with sickle cell disease: a systematic review.","volume":"167","author":"Rea","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"jrv220010r113","doi-asserted-by":"publisher","DOI":"10.1002\/ggn2.v2.1","article-title":"Sickle cell disease is a global prototype for integrative research and healthcare.","volume":"2","author":"Royal","year":"2021","journal-title":"Adv Genet"},{"issue":"6","key":"jrv220010r114","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review.","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep"},{"issue":"4","key":"jrv220010r115","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ajh.v96.4","article-title":"Impact of sickle cell disease on patients\u2019 daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).","volume":"96","author":"Osunkwo","year":"2021","journal-title":"Am J Hematol"},{"key":"jrv220010r4","volume-title":"Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action","author":"National Academies of Sciences, Engineering, and Medicine","year":"2020"},{"key":"jrv220010r11","unstructured":"Association of Public Health Laboratories; Centers for Disease Control and Prevention. Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up. Published December 2015. Accessed May 7, 2022.? https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/documents\/nbs_hemoglobinpathy-testing_122015.pdf"},{"key":"jrv220010r21","unstructured":"National Heart Lung and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Published September 2014. Accessed May 8, 2022.? https:\/\/www.nhlbi.nih.gov\/health-topics\/evidence-based-management-sickle-cell-disease"},{"key":"jrv220010r108","unstructured":"Office of National Statistics. Life expectancy at birth and at age 65 by local areas in England and Wales: 2012 to 2014: regional life expectancy at birth. Accessed May 1, 2022. http:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/lifeexpectancyatbirthandatage65bylocalareasinenglandandwales\/2015-11-04#regional-life-expectancy-at-birth"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2793821\/jama_kavanagh_2022_rv_220010_1656542439.96552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T11:05:26Z","timestamp":1657019126000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2793821"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.10233","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,5]]}}}